Hazer Group licences a process that splits natural gas into hydrogen and graphite without the carbon emissions of conventional methods. At A$0.38 versus a fair value of A$0.042, the stock trades at roughly nine times what the analysis supports — a gap driven almost entirely by speculative option value rather than near-term cash generation. The company has proven the technology works in the lab; the unanswered question is whether it can sell it commercially.

The best fit for Hazer is a thematic investor with a five-to-eight-year horizon, high tolerance for binary outcomes, and the discipline to size the position accordingly — well below one percent of a diversified portfolio. The technology is credible, the KBR alliance is a genuine structural advantage, and the graphite co-product provides a second pathway to value that most peers lack entirely. None of that justifies the current price; but for an investor who has done the work and wants exposure to non-electrolytic clean hydrogen, this is where the option lives.

Hazer Group owns a proprietary process that uses iron ore as a catalyst to split natural gas into hydrogen and solid graphite — producing neither the CO₂ of conventional hydrogen nor the capital intensity of green electrolysis. The business model is pure IP licensing: Hazer earns study fees while projects are in development, a one-off licence fee at final investment decision, and ongoing royalties once a plant is producing hydrogen and graphite at scale.

The company's first half of FY26 delivered exactly what the model predicts at this stage — almost nothing on the revenue line. Total contracted income was A$18,000. What did improve meaningfully was the cost structure: operating expenses fell 27% year-on-year as the Commercial Demonstration Plant was wound down and discretionary R&D was cut. Cash burn slowed to A$2.3m annually, extending the runway to four to six years without a capital raise. The KBR-led Product Development Program completed on schedule, and the first paid engineering study — a concept evaluation for EnergyPathways in the UK — confirmed that customers will pay for Hazer's work.

The investment case is a long-duration option on commercial licensing success. The KBR alliance gives a micro-cap access to 200-plus industrial customers globally, which is a genuine structural advantage. The graphite co-product — a critical mineral increasingly constrained by Chinese export controls — provides a second monetisation pathway that no hydrogen-only competitor can replicate. Against that, the company has signed zero production licences in five years of commercial activity, every major clean hydrogen project has taken longer than the market expected, and the current share price implies a success probability and a discount rate that our analysis cannot support. At A$0.38 versus a fair value of A$0.042, the stock is approximately 89% overvalued.

What happened?

The H1 FY26 result was operationally credible but commercially thin. Revenue of A$18,000 was offset by A$2.5m in R&D tax rebates and A$0.2m in interest — so the company did not run short of cash. The more meaningful development was cost discipline: consulting and R&D spend fell 59% as the Commercial Demonstration Plant completed its work, and total operating expenses dropped from A$7.6m to A$5.5m in the half. The KBR Product Development Program finished on schedule, the EnergyPathways concept study generated Hazer's first contracted study revenue, and the graphite application partnership with POSCO was extended for a second year.

What's next?

The next twelve months pivot entirely on whether KBR converts its engineering pipeline into binding licence agreements. The KBR Product Development Program has produced a commercial-ready large-scale design; the question is whether industrial customers — FortisBC in Canada, EnergyPathways in the UK, and others in Hazer's disclosed pipeline — progress from concept studies to final investment decisions. Any binding production licence announcement would be the single most important event in Hazer's commercial history.

On the graphite side, the POSCO partnership extension keeps open the possibility of commercial offtake. Chinese export controls on graphite are tightening, which structurally improves the economics for a non-Chinese source. The cash balance of A$14.8m provides runway, but the model shows the balance approaching A$3m by FY28 — a capital raise is likely if no production licence has been signed by then.

First royalty cash flows are not expected before FY31 in the base case, and FY33 is when the model first projects positive EBITDA. Investors pricing the stock at A$0.38 are implicitly assuming this timeline compresses significantly.

The valuation rests on a single uncomfortable fact: Hazer's entire equity value is a bet on cash flows that do not begin for at least five years. At an 18.5% discount rate — mechanically derived from current Australian risk-free rates and Hazer's risk profile — the present value of near-term losses overwhelms the present value of eventual royalties in the base case. The only scenario where the current price is defensible is one where the market is right to apply a much lower discount rate (implying ~12%) and where KBR delivers six or more production licences. That combination cannot be ruled out, but it requires both the interest rate environment to normalise significantly and Hazer to outperform every commercial milestone it has set to date.

The single biggest risk is straightforward: zero production licences signed by December 2027. FortisBC has been in site selection for three years without a decision. EnergyPathways is at concept stage. If neither — nor any other project in the KBR pipeline — reaches a binding licence agreement within two years, the thesis is structurally impaired. At that point, the stock would likely re-rate toward net tangible asset value of A$0.051, itself eroding with each passing quarter of cash burn. The NTA floor provides some comfort; the gap between it and the current price does not.